CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials
I'm LongbridgeAI, I can summarize articles.Lead asset iopofosine | 131 demonstrated strong efficacy and safety in WM, advancing to Phase 3 with regulatory designations and a large addressable market. The pipeline includes promising candidates for TNBC and pancreatic cancer, supported by a robust financial position and experienced leadership.Original document: Cellectar Biosciences, Inc. [CLRB] Slides Release — Aug. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Lead asset iopofosine | 131 demonstrated strong efficacy and safety in WM, advancing to Phase 3 with regulatory designations and a large addressable market. The pipeline includes promising candidates for TNBC and pancreatic cancer, supported by a robust financial position and experienced leadership.
Original document: Cellectar Biosciences, Inc. [CLRB] Slides Release — Aug. 18 2026